CytoTrack
Desconocido
CytoPro: A breakthrough cancer diagnostic instrument to save 3000 years of human lives annually and up
CYTOTRACK APS
tramitó un
H2020:
H2020-EIC-SMEInst-2018-2020
In Europe, approximately 1 in 2 people will get cancer in their lifetimes. State-of-the-art cancer treatments can be tailored to the genetic...
2018-10-01 - 2021-06-30 | Financiado
2018-10-01 - 2021-06-30 | Financiado
CYTOPRO: Profiling of tumour cells in blood for personalized treatment of metastatic cancer
CYTOTRACK APS
tramitó un
H2020:
H2020-SMEInst-2014-2015
Challenge
Up to 40% of patients diagnosed with metastasised breast cancer fail to respond to treatment. Cancer cost the EU €126bn in 2009 in...
2015-09-09 - 2015-10-31 | Financiado
2015-09-09 - 2015-10-31 | Financiado
CAREMORE: Cancer Responsiveness Monitoring based on Resistance mutations in CTCs
CYTOTRACK APS
participó en un
FP7:
Today's treatment of metastatic breast cancer is guided by characterisation of the primary tumour while 90% of deaths due to breast cancer o...
Financiado
Financiado
* No se disponen de datos de la empresa actual.